Drugs / PB-201
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03973515 | Aug → Dec 2019 | type 2 diabetes mellitus | PegBio Co., Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05326490 | May 2022 → Sep 2024 | type 2 diabetes mellitus | PegBio Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05102149 | Sep 2021 → Nov 2023 | type 2 diabetes mellitus | PegBio Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB-201 | “PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies.” PMID 34805810 ↗ Nov 2021 |
| Route | Oral | “In each period, they received oral placebo or PB-201 (50+50, 100+50, or 100+100 mg split doses) for 7 days.” PMID 34805810 ↗ Nov 2021 |